21 results on '"Gormly K"'
Search Results
2. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol
- Author
-
Vatandoust, S, Wattchow, D, Sposato, L, Michael, MZ, Leung, J, Gormly, K, Chen, G, Symonds, EL, Tie, J, Papanicolas, LE, Woods, S, Gebski, V, Mead, K, Kuruni, A, Karapetis, CS, Vatandoust, S, Wattchow, D, Sposato, L, Michael, MZ, Leung, J, Gormly, K, Chen, G, Symonds, EL, Tie, J, Papanicolas, LE, Woods, S, Gebski, V, Mead, K, Kuruni, A, and Karapetis, CS
- Abstract
BACKGROUND: Rectal Cancer is a common malignancy. The current treatment approach for patients with locally advanced rectal cancer involves neoadjuvant chemoradiotherapy followed by surgical resection of the rectum. The resection can lead to complications and long-term consequences. A clinical complete response is observed in some patients after chemoradiotherapy. A number of recent studies have shown that patients can be observed safely after completing chemoradiotherapy (without surgery), provided clinical complete response has been achieved. In this approach, resection is reserved for cases of regrowth. This is called the watch and wait approach. This approach potentially avoids unnecessary surgical resection of the rectum and the resulting complications. In this study, we will prospectively investigate this approach. METHODS: Adult patients with a diagnosis of rectal cancer planned to receive neoadjuvant long course chemoradiotherapy (± subsequent combination chemotherapy) will be consented into the study prior to commencing treatment. After completing the chemoradiotherapy (± subsequent combination chemotherapy), based on the clinical response, subjects will be allocated to one of the following arms: subjects who achieved a clinical complete response will be allocated to the watch and wait arm and others to the standard management arm (which includes resection). The aim of the study is to determine the rate of local failure and other safety and efficacy outcomes in the watch and wait arm. Patient reported outcome measures and the use of biomarkers as part of the clinical monitoring will be studied in both arms of the study. DISCUSSION: This study will prospectively investigate the safety of the watch and wait approach. We will investigate predictive biomarkers (molecular biomarkers and imaging biomarkers) and patient reported outcome measures in the study population and the cost effectiveness of the watch and wait approach. This study will also help evaluate a d
- Published
- 2022
3. The additional value of multiparametric prostate MRI in routine practice: An audit of dominant nodule detection and T3 extension at 1.5T
- Author
-
Raeside, M, Gormly, K, Sutherland, P, and Cohen, P
- Published
- 2014
4. Standardised tumour, node and metastasis reporting of oncology CT scans
- Author
-
Gormly, K LM
- Published
- 2009
- Full Text
- View/download PDF
5. SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial.
- Author
-
Jameson, MB, Gormly, K, Espinoza, D, Hague, W, Asghari, G, Jeffery, GM, Price, TJ, Karapetis, CS, Arendse, M, Armstrong, J, Childs, J, Frizelle, FA, Ngan, S, Stevenson, A, Oostendorp, M, Ackland, SP, Jameson, MB, Gormly, K, Espinoza, D, Hague, W, Asghari, G, Jeffery, GM, Price, TJ, Karapetis, CS, Arendse, M, Armstrong, J, Childs, J, Frizelle, FA, Ngan, S, Stevenson, A, Oostendorp, M, and Ackland, SP
- Abstract
BACKGROUND: Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late toxicities of pelvic radiation. Major tumour regression following pCRT has strong prognostic significance and can be assessed in vivo using MRI-based tumour regression grading (mrTRG) or after surgery using pathological TRG (pathTRG). METHODS: A double-blind phase 2 trial will randomise 222 patients planned to receive long-course fluoropyrimidine-based pCRT for rectal adenocarcinoma at 18+ sites in New Zealand and Australia. Patients will receive simvastatin 40 mg or placebo daily for 90 days starting 1 week prior to standard pCRT. Pelvic MRI 6 weeks after pCRT will assess mrTRG grading prior to surgery. The primary objective is rates of favourable (grades 1-2) mrTRG following pCRT with simvastatin compared to placebo, considering mrTRG in 4 ordered categories (1, 2, 3, 4-5). Secondary objectives include comparison of: rates of favourable pathTRG in resected tumours; incidence of toxicity; compliance with intended pCRT and trial medication; proportion of patients undergoing surgical resection; cancer outcomes and pathological scores for radiation colitis. Tertiary objectives include: association between mrTRG and pathTRG grouping; inter-observer agreement on mrTRG scoring and pathTRG scoring; studies of T-cell infiltrates in diagnostic biopsies and irradiated resected normal and malignant tissue; and the effect of simvastatin on markers of systemic inflammation (modified Glasgow prognostic score and the neutrophil-lymphocyte ratio). Trial recruitment commenced April 2018. DISCUSSION: When completed this study will be able to observe meaningful differences in measurable tumour outcome parameters and/or toxicity from simvastatin. A positive result will require a larger RCT to confirm and validate the merit of statins in the preope
- Published
- 2019
6. Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG).
- Author
-
Siddiqui, M. R. S., Gormly, K. L., Bhoday, J., Balyansikova, S., Battersby, N. J., Chand, M., Rao, S., Tekkis, P., Abulafi, A. M., and Brown, G.
- Subjects
- *
RADIOLOGISTS , *RECTAL cancer , *PREOPERATIVE care , *MAGNETIC resonance imaging , *SPONTANEOUS cancer regression , *ANTINEOPLASTIC agents , *CLINICAL competence , *CLINICAL trials , *COMPARATIVE studies , *DIFFERENTIAL diagnosis , *DIAGNOSTIC imaging , *RESEARCH methodology , *MEDICAL cooperation , *COMPUTERS in medicine , *RESEARCH , *EVALUATION research , *TREATMENT effectiveness , *RESEARCH bias , *TUMOR grading , *TUMOR treatment ,RECTUM tumors ,RESEARCH evaluation - Abstract
Aim: To investigate whether the magnetic resonance imaging (MRI) tumour regression grading (mrTRG) scale can be taught effectively resulting in a clinically reasonable interobserver agreement (>0.4; moderate to near perfect agreement).Materials and Methods: This study examines the interobserver agreement of mrTRG, between 35 radiologists and a central reviewer. Two workshops were organised for radiologists to assess regression of rectal cancers on MRI staging scans. A range of mrTRGs on 12 patient scans were used for assessment.Results: Kappa agreement ranged from 0.14-0.82 with a median value of 0.57 (95% CI: 0.37-0.77) indicating good overall agreement. Eight (26%) radiologists had very good/near perfect agreement (κ>0.8). Six (19%) radiologists had good agreement (0.8≥κ>0.6) and a further 12 (39%) had moderate agreement (0.6≥κ>0.4). Five (16%) radiologists had a fair agreement (0.4≥κ>0.2) and two had poor agreement (0.2>κ). There was a tendency towards good agreement (skewness: 0.92). In 65.9% and 90% of cases the radiologists were able to correctly highlight good and poor responders, respectively.Conclusions: The assessment of the response of rectal cancers to chemoradiation therapy may be performed effectively using mrTRG. Radiologists can be taught the mrTRG scale. Even with minimal training, good agreement with the central reviewer along with effective differentiation between good and intermediate/poor responders can be achieved. Focus should be on facilitating the identification of good responders. It is predicted that with more intensive interactive case-based learning a κ>0.8 is likely to be achieved. Testing and retesting is recommended. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Magnetic Resonance Imaging in the staging of cervical carcinoma: A pictorial review.
- Author
-
Smith, G. E. C. and Gormly, K. L. M.
- Subjects
- *
CERVICAL cancer , *TUMOR classification , *MAGNETIC resonance imaging , *IMAGING of cancer , *LYMPHATIC tumors - Abstract
The purposes of diagnostic imaging in cervical carcinoma are to determine the size and extent of the tumour for accurate staging and to establish lymph node status. Historically, cervical tumours were staged by clinical examination and by examination under anaesthesia according to the International Federation of Gynecology and Obstetrics staging system. This system does not incorporate imaging findings or lymph node status, but it is now accepted that cross-sectional imaging, and in particular MRI, has an important role to play in the staging of these tumours. We carried out an audit of all patients having a staging MRI for suspected cervical carcinoma in South Australia and the Northern Territory for 2 years from January 2005. This was the first time the clinicians had been offered routine MRI, and despite the strong supporting published reports, they had some reservations about its performance. Our audit covered a wide range of tumour stages and provided a good teaching resource for radiologists and clinicians alike. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
8. A study of the effects of corticotrophin-releasing factor and dexamethasone on the secretion of the pituitary hormone corticotrophin (ACTH) in cultured ovine pituitary cells
- Author
-
Gormly, K. J.
- Subjects
- corticotrophin ACTH, corticotrophin-releasing factor (CRF), dexamethasone (DEX), ovine pituitary cells, pituitary hormone secretion, glucocorticoids, sheep physiology, endocrinology, ANZSRC::110306 Endocrinology, ANZSRC::07 Agricultural and Veterinary Sciences
- Abstract
It was the aim of this study to determine the ways in which the secretion of the pituitary hormone ACTH was affected by corticotrophin-releasing factor ("CRF") and dexamethasone ("DEX") in cultured ovine pituitary cells. Only recently has the isolation, sequence and characterisation of ovine hypothalamic CRF been reported. The characterisation of a CRF that stimulated the secretion of corticotrophin-like and B-endorphin like immunoreactivities in vitro and in vivo was certainly a major discovery, and indeed remarkable for it was, among other things, the identification of the chemical that triggers the body’s stress reactions. Its identification has, in fact, led to a much better understanding of the endocrine response to stress. As described by Fink (1981) one more factor, possibly the most vital, has been isolated. It was Vale, Speiss, Rivier and Rivier who first reported the molecular structure of the releasing factor, in 1981 at the Salk Institute. Direct evidence for an ACTH releasing factor was initially reported by Guillemin and Rosenberg and Saffran and Schally in 1955. Although it was the first of the pituitary releasing factors to be described its early history was marked by controversy. Attempts to isolate the CRF in its pure state were hampered by the complexity of assays, interference by vasopressin and similar ACTH releasing substances, the loss of activity during purification, and other reasons (Chang, Huang, Arimura, Redding, Coy, Saffran, Kong, Hamilton, Cohn and Schally 1981). The breakthrough by Vale and his team in 1981 with their purification, sequence analysis and total synthesis of the 41 residue peptide was therefore an important advance. Since the determination of the primary structure of CRF and its subsequent synthesis, it has been found to exhibit high potency and intrinsic activity to stimulate ACTH release both in vivo and in vitro in a number of species including man, rat, sheep and cattle. CRF is thus well documented as the principal neuroregulator of the secretion of ACTH and other proopiomelanocortin products of the anterior pituitary gland (Rivier, Rivier and Vale 1984). It is also well established that glucocorticoids exert inhibitory feedback effects in the physiological control of ACTH secretion (Yates and Maran 1974; Fortier 1966). They are potent inhibitors of ACTH release (Vale and Rivier 1977; Raymond, Lepine, Lissitsky, Cote, Coy and Labrie 1979; Kraicer and Milligan 1970) in both man and experimental animals, (Fleischer and Rawls 1970). The site of their blocking action however, whether central or at the pituitary itself, has been the subject of controversy. The relatively recent appearance of CRF, and its importance in the clinical sphere, (already it has been established as a useful tool of endocrine evaluation in patients with hypothalamic, pituitary disorders Orth, DeBold, De Cherney, Jackson, Alexander, Rivier, Rivier, Speiss and Vale 1982; Muller, Stalla and Vonwerder 1983), make CRF an interesting hormone to investigate. Dexamethasone was selected for its well known affects on the cells in question and static culture chosen because of its value as a model for in vivo events. Despite the established facts about a number of aspects of this study, the combination of experimental variables i.e. the selection of in vitro static culture techniques as opposed to in vivo studies, and the use of ovine cells rather than the commonly utilized rat pituitary cells, made it a unique investigation. At the outset of this project, therefore, the general effects of CRF and dexamethasone in cultured rat adenohypophyseal cells were well documented but little was known of their activity in cultured ovine anterior pituitary cells.
- Published
- 1986
9. Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
- Author
-
O'Callaghan M, Bulamu N, Gormly K, and Jay A
- Subjects
- Male, Humans, Prospective Studies, Prevalence, Magnetic Resonance Imaging, Prostate pathology, Prostatic Neoplasms epidemiology, Prostatic Neoplasms pathology
- Published
- 2024
- Full Text
- View/download PDF
10. MRI restaging of rectal cancer: The RAC (Response-Anal canal-CRM) analysis joint consensus guidelines of the GRERCAR and GRECCAR groups.
- Author
-
Nougaret S, Rousset P, Lambregts DMJ, Maas M, Gormly K, Lucidarme O, Brunelle S, Milot L, Arrivé L, Salut C, Pilleul F, Hordonneau C, Baudin G, Soyer P, Brun V, Laurent V, Savoye-Collet C, Petkovska I, Gerard JP, Cotte E, Rouanet P, Catalano O, Denost Q, Tan RB, Frulio N, and Hoeffel C
- Subjects
- Humans, Neoplasm Staging, Magnetic Resonance Imaging methods, Consensus, Neoadjuvant Therapy, Anal Canal, Rectal Neoplasms diagnostic imaging
- Abstract
Purpose: To develop guidelines by international experts to standardize data acquisition, image interpretation, and reporting in rectal cancer restaging with magnetic resonance imaging (MRI)., Materials and Methods: Evidence-based data and experts' opinions were combined using the RAND-UCLA Appropriateness Method to attain consensus guidelines. Experts provided recommendations for reporting template and protocol for data acquisition were collected; responses were analysed and classified as "RECOMMENDED" versus "NOT RECOMMENDED" (if ≥ 80% consensus among experts) or uncertain (if < 80% consensus among experts)., Results: Consensus regarding patient preparation, MRI sequences, staging and reporting was attained using the RAND-UCLA Appropriateness Method. A consensus was reached for each reporting template item among the experts. Tailored MRI protocol and standardized report were proposed., Conclusion: These consensus recommendations should be used as a guide for rectal cancer restaging with MRI., Competing Interests: Disclosure of interest The authors have no conflicts of interest to disclose in relation with this article., (Copyright © 2023. Published by Elsevier Masson SAS.)
- Published
- 2023
- Full Text
- View/download PDF
11. Optimising CT-chest protocols and the added value of venous-phase contrast timing; Observational case-control.
- Author
-
Croft M, Lim W, Lavender N, and Gormly K
- Subjects
- Angiography methods, Case-Control Studies, Humans, Thorax, Tomography, X-Ray Computed methods, Contrast Media, Pulmonary Embolism diagnostic imaging
- Abstract
Introduction: To optimize CT chest protocol by comparing venous contrast timing with arterial timing for contrast opacification in vessels, qualitative image quality and radiologists' satisfaction and diagnostic confidence in assessing for potential nodal, pleural and pulmonary disease in general oncology outpatients., Method: Matched case-control study performed following CT protocol update. 92 patients with a range of primary malignancies with 2 CT chests in a 2-year period, one with an arterial phase protocol and the second in the 60 second venous phase, were included. Contrast attenuation in aorta, pulmonary artery and liver were measured. Subjective measurements assessed perivenous artefact, confidence in nodal pleural and pulmonary assessment and presence of pulmonary emboli. Statistical analysis was performed using paired and unpaired t-tests., Results: Venous-phase CT demonstrated more consistent enhancement of the vessels, with higher attenuation of the nodes, pulmonary and pleural lesions. There was a significant reduction in perivenous beam hardening artefact on venous-phase CT (P < 0.001). Diagnostic confidence was significantly higher for nodal assessment and pleural abnormality visibility (P < 0.001) and pleural assessment (P < 0.05). There was no significant difference in pulmonary mass visibility. There was adequate enhancement to diagnose significant pulmonary emboli (PE) with 4 incidental PEs detected on the venous phase, extending to segmental vessels., Conclusion: Venous-phase CT chest performs better than arterial-phase on all fronts, without compromising assessment of incidental pulmonary emboli. When intravenous contrast is indicated in a routine chest CT (excluding a CT-angiogram), the default timing should be a venous or 60s phase., (© 2021 The Royal Australian and New Zealand College of Radiologists.)
- Published
- 2022
- Full Text
- View/download PDF
12. Structured and shared MRI staging lexicon and report of rectal cancer: A consensus proposal by the French Radiology Group (GRERCAR) and Surgical Group (GRECCAR) for rectal cancer.
- Author
-
Nougaret S, Rousset P, Gormly K, Lucidarme O, Brunelle S, Milot L, Salut C, Pilleul F, Arrivé L, Hordonneau C, Baudin G, Soyer P, Brun V, Laurent V, Savoye-Collet C, Petkovska I, Gerard JP, Rullier E, Cotte E, Rouanet P, Beets-Tan RGH, Frulio N, and Hoeffel C
- Subjects
- Consensus, Humans, Magnetic Resonance Imaging methods, Neoplasm Staging, Radiology, Rectal Neoplasms diagnostic imaging, Rectal Neoplasms pathology
- Abstract
Purpose: To develop French guidelines by experts to standardize data acquisition, image interpretation, and reporting in rectal cancer staging with magnetic resonance imaging (MRI)., Materials and Methods: Evidence-based data and opinions of experts of GRERCAR (Groupe de REcherche en Radiologie sur le CAncer du Rectum [i.e., Rectal Cancer Imaging Research Group]) and GRECCAR (Groupe de REcherche en Chirurgie sur le CAncer du Rectum [i.e., Rectal Cancer Surgery Research Group]) were combined using the RAND-UCLA Appropriateness Method to attain consensus guidelines. Experts scoring of reporting template and protocol for data acquisition were collected; responses were analyzed and classified as "Recommended" versus "Not recommended" (when ≥ 80% consensus among experts) or uncertain (when < 80% consensus among experts)., Results: Consensus regarding patient preparation, MRI sequences, staging and reporting was attained using the RAND-UCLA Appropriateness Method. A consensus was reached for each reporting template item among the experts. Tailored MRI protocol and standardized report were proposed., Conclusion: These consensus recommendations should be used as a guide for rectal cancer staging with MRI., (Copyright © 2021 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
13. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.
- Author
-
Vatandoust S, Wattchow D, Sposato L, Michael MZ, Leung J, Gormly K, Chen G, Symonds EL, Tie J, Papanicolas LE, Woods S, Gebski V, Mead K, Kuruni A, and Karapetis CS
- Subjects
- Adult, Biomarkers, Tumor analysis, Female, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Rectal Neoplasms mortality, Survival Rate, Treatment Outcome, Neoadjuvant Therapy, Rectal Neoplasms therapy, Watchful Waiting methods
- Abstract
Background: Rectal Cancer is a common malignancy. The current treatment approach for patients with locally advanced rectal cancer involves neoadjuvant chemoradiotherapy followed by surgical resection of the rectum. The resection can lead to complications and long-term consequences. A clinical complete response is observed in some patients after chemoradiotherapy. A number of recent studies have shown that patients can be observed safely after completing chemoradiotherapy (without surgery), provided clinical complete response has been achieved. In this approach, resection is reserved for cases of regrowth. This is called the watch and wait approach. This approach potentially avoids unnecessary surgical resection of the rectum and the resulting complications. In this study, we will prospectively investigate this approach., Methods: Adult patients with a diagnosis of rectal cancer planned to receive neoadjuvant long course chemoradiotherapy (± subsequent combination chemotherapy) will be consented into the study prior to commencing treatment. After completing the chemoradiotherapy (± subsequent combination chemotherapy), based on the clinical response, subjects will be allocated to one of the following arms: subjects who achieved a clinical complete response will be allocated to the watch and wait arm and others to the standard management arm (which includes resection). The aim of the study is to determine the rate of local failure and other safety and efficacy outcomes in the watch and wait arm. Patient reported outcome measures and the use of biomarkers as part of the clinical monitoring will be studied in both arms of the study., Discussion: This study will prospectively investigate the safety of the watch and wait approach. We will investigate predictive biomarkers (molecular biomarkers and imaging biomarkers) and patient reported outcome measures in the study population and the cost effectiveness of the watch and wait approach. This study will also help evaluate a defined monitoring schedule for patients managed with the watch and wait approach. This protocol covers the first two years of follow up, we are planning a subsequent study which covers year 3-5 follow up for the study population., Trial Registration: Name of the registry: Australia and New Zealand Clinical Trials Registry (ANZCTR)., Trial Registration Number: Trial ID: ACTRN12619000207112 Registered 13 February 2019, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376810., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
14. Rectal MRI: the importance of high resolution T2 technique.
- Author
-
Gormly K
- Subjects
- Humans, Magnetic Resonance Imaging, Rectal Neoplasms diagnostic imaging
- Abstract
The cornerstone of the MRI rectal examination is the high resolution (HR) T2 sequence. There is varied definition of this term in national guidelines with a resultant wide variation in the spatial resolution of sequences termed 'high resolution'. This article comments on the importance of the original three dimensional HR T2 definition of 0.6 × 0.6 in plane resolution × 3 mm slice thickness with 4 NEX and demonstrates the effect reduced spatial resolution can have on image appearance and interpretation., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
15. SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial.
- Author
-
Jameson MB, Gormly K, Espinoza D, Hague W, Asghari G, Jeffery GM, Price TJ, Karapetis CS, Arendse M, Armstrong J, Childs J, Frizelle FA, Ngan S, Stevenson A, Oostendorp M, and Ackland SP
- Subjects
- Female, Humans, Male, Middle Aged, Chemoradiotherapy, Double-Blind Method, Neoplasm Grading, Preoperative Care, Simvastatin administration & dosage, Treatment Outcome, Clinical Trials, Phase II as Topic, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Rectal Neoplasms drug therapy, Rectal Neoplasms pathology, Rectal Neoplasms radiotherapy
- Abstract
Background: Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late toxicities of pelvic radiation. Major tumour regression following pCRT has strong prognostic significance and can be assessed in vivo using MRI-based tumour regression grading (mrTRG) or after surgery using pathological TRG (pathTRG)., Methods: A double-blind phase 2 trial will randomise 222 patients planned to receive long-course fluoropyrimidine-based pCRT for rectal adenocarcinoma at 18+ sites in New Zealand and Australia. Patients will receive simvastatin 40 mg or placebo daily for 90 days starting 1 week prior to standard pCRT. Pelvic MRI 6 weeks after pCRT will assess mrTRG grading prior to surgery. The primary objective is rates of favourable (grades 1-2) mrTRG following pCRT with simvastatin compared to placebo, considering mrTRG in 4 ordered categories (1, 2, 3, 4-5). Secondary objectives include comparison of: rates of favourable pathTRG in resected tumours; incidence of toxicity; compliance with intended pCRT and trial medication; proportion of patients undergoing surgical resection; cancer outcomes and pathological scores for radiation colitis. Tertiary objectives include: association between mrTRG and pathTRG grouping; inter-observer agreement on mrTRG scoring and pathTRG scoring; studies of T-cell infiltrates in diagnostic biopsies and irradiated resected normal and malignant tissue; and the effect of simvastatin on markers of systemic inflammation (modified Glasgow prognostic score and the neutrophil-lymphocyte ratio). Trial recruitment commenced April 2018., Discussion: When completed this study will be able to observe meaningful differences in measurable tumour outcome parameters and/or toxicity from simvastatin. A positive result will require a larger RCT to confirm and validate the merit of statins in the preoperative management of rectal cancer. Such a finding could also lead to studies of statins in conjunction with chemoradiation in a range of other malignancies, as well as further exploration of possible mechanisms of action and interaction of statins with both radiation and chemotherapy. The translational substudies undertaken with this trial will provisionally explore some of these possible mechanisms, and the tissue and data can be made available for further investigations., Trial Registration: ANZ Clinical Trials Register ACTRN12617001087347. (www.anzctr.org.au, registered 26/7/2017) Protocol Version: 1.1 (June 2017).
- Published
- 2019
- Full Text
- View/download PDF
16. Prostate MRI evolution in clinical practice: Audit of tumour detection and staging versus prostatectomy with staged introduction of multiparametric MRI and Prostate Imaging Reporting and Data System v2 reporting.
- Author
-
Raeside M, Low A, Cohen P, Sutherland P, and Gormly K
- Subjects
- Humans, Male, Neoplasm Staging, Prostate diagnostic imaging, Prostate pathology, Prostate surgery, Prostatic Neoplasms surgery, Retrospective Studies, Magnetic Resonance Imaging methods, Medical Audit methods, Prostatectomy, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology, Radiology Information Systems statistics & numerical data
- Abstract
Introduction: We conducted a retrospective audit to compare dominant nodule detection and local staging before and after the introduction of functional sequences and PI-RADS v2 reporting to MRI prostate scans in routine private practice., Methods: A retrospective audit was performed of 245 patients in four separate groups undergoing robotic prostatectomy for prostate cancer by a single urologist between 2009 and 2017. The initial 100 consecutive patients had T2 imaging only. The next 43 patients had T2 and DWI. 52 subsequent patients had T2, DWI and DCE sequences (mpMRI). A final 50 consecutive patients had mpMRI using PI-RADS v2 reporting. Preoperative MRI reports were compared with prostatectomy histopathology to determine the sensitivity of MRI in detecting dominant tumour nodule and T3 extension., Results: The addition of DWI and DCE sequences improved sensitivity for detection of dominant tumour nodule, with a significant further increase using PI-RADS v2 reporting (38% for T2 vs. 62% for T2/DWI vs. 67% for mpMRI vs 91% for PI-RADS v2). The accuracy of detecting T3 disease was initially very low. The use of additional imaging techniques did not significantly influence this, but the use of a three category likelihood of extraprostatic extension in the PI-RADS v2 group had a significant increase in detection of T3 disease (sensitivity 27% vs. 23% vs. 38% vs 63%)., Conclusion: This audit tracks the significant improvements in MRI detection of prostate cancer dominant tumour nodule and T3 extension in patients undergoing prostatectomy with changing techniques and reporting standards in routine clinical practice., (© 2019 The Royal Australian and New Zealand College of Radiologists.)
- Published
- 2019
- Full Text
- View/download PDF
17. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
- Author
-
Hoffmann R, Logan C, O'Callaghan M, Gormly K, Chan K, and Foreman D
- Subjects
- Adenocarcinoma surgery, Aged, Aged, 80 and over, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Humans, Magnetic Resonance Imaging methods, Male, Middle Aged, Neoplasm Grading, Observer Variation, Prostate pathology, Prostatectomy, Prostatic Neoplasms surgery, ROC Curve, Adenocarcinoma diagnostic imaging, Adenocarcinoma pathology, Magnetic Resonance Imaging standards, Practice Guidelines as Topic, Prostate diagnostic imaging, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology
- Abstract
Introduction: Multiparametric MRI (mpMRI) is useful in detecting anterior prostate tumours. Due to the location of anterior tumours, they are often diagnosed with a large size and may be suspicious for extra-prostatic extension (EPE). We aim to evaluate whether PI-RADS v2 is more accurate in assessing anterior prostate lesions identified on mpMRI compared to PI-RADS v1., Methods: Patients with anterior prostate lesions diagnosed on mpMRI who proceeded to a cognitive fusion transperineal prostate biopsy were identified. Each mpMRI was blinded and read by two experienced prostate MRI radiologists and assigned a PI-RADS v1 and PI-RADS v2 score, and the presence of EPE was estimated. Correlation was made with transperineal histopathology and, where relevant, radical prostatectomy histopathology. Concordance measures between PI-RADS v1 and PI-RADS v2, and between examiners of the same PI-RADS score were calculated using a weighted kappa., Results: Fifty-eight consecutive men were identified. Concordance between the examiners for PI-RADS v1 and for v2 showed substantial agreement (version 1: weighted kappa 0.71; version 2: weighted kappa 0.69). There was no difference in accuracy when using PI-RADS v1 or PI-RADS v2 to predict clinically significant cancer. There was poor correlation between EPE measured on mpMRI compared with EPE in radical prostatectomy histopathology., Conclusion: PI-RADS v2 is reproducible between radiologists but does not have improved accuracy for diagnosing anterior tumours of the prostate when compared to PI-RADS v1. Multiparametric MRI is accurate at detecting anterior tumours with a sensitivity of 86-88%.
- Published
- 2018
- Full Text
- View/download PDF
18. Uncommon Anal Neoplasms.
- Author
-
Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, and Segelov E
- Subjects
- Humans, Incidence, Quality of Life, Anus Neoplasms pathology, Lymphoma pathology, Melanoma pathology, Neuroendocrine Tumors pathology
- Abstract
Uncommon neoplasms of the anal canal are associated with significant diagnostic dilemma in clinical practice and a high index of suspicion and pathologic expertise is needed. The incidence is likely to increase, particularly of small, incidental lesions found because of use of more frequent colonoscopy and high-definition MRI. Generally treatment follows that of the same histologic subtype in other anatomic location. Surgical intervention is the cornerstone for cure in early/localized disease; however, removal of the anal canal is associated with significant morbidities and quality of life issues. A centralized global registry/database established under the auspices of the International Rare Care Initiative collaboration would be useful., (Crown Copyright © 2016. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
19. Primary pericardial mesothelioma presenting as multiple pericardial masses on CT.
- Author
-
Raeside MC, Gormly K, Neuhaus SJ, Kotasek D, and James C
- Abstract
We present the case of a 67-year-old male who was found to have multiple enhancing pericardial masses on CT imaging for investigation of weight loss and was subsequently diagnosed with primary pericardial mesothelioma. Although rare, pericardial mesothelioma is the most common primary malignancy of the pericardium and should be considered in the differential diagnosis of pericardial effusion, pericardial thickening or discreet pericardial mass. It is important for radiologists to be aware of pericardial mesothelioma as its clinical presentation is non-specific and it may be incidentally noted on radiological studies for investigation of apparently non-related symptoms. The prognosis of primary pericardial mesothelioma is universally poor.
- Published
- 2016
- Full Text
- View/download PDF
20. Calcified nodal metastasis from squamous cell carcinoma of the head and neck.
- Author
-
Gormly K and Glastonbury CM
- Subjects
- Aged, Calcinosis diagnostic imaging, Carcinoma, Squamous Cell diagnostic imaging, Diagnosis, Differential, Head and Neck Neoplasms diagnostic imaging, Humans, Male, Tomography, X-Ray Computed, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms pathology, Lymphatic Metastasis diagnostic imaging
- Abstract
Calcification within cervical lymph nodes is relatively rare, and most commonly ascribed to benign inflammatory or infectious processes. We present a case of a calcified submandibular nodal metastasis from squamous cell carcinoma of the lip and review the current published literature on nodal calcifications in the neck. To the authors' knowledge, calcification resulting from metastatic squamous cell carcinoma of the head and neck has been described only once previously.
- Published
- 2004
- Full Text
- View/download PDF
21. Assessment of an online radiology reporting system.
- Author
-
Gormly KL and Langlois SL
- Subjects
- Evaluation Studies as Topic, Humans, Radiology Department, Hospital, Time Factors, Online Systems, Radiology Information Systems
- Abstract
This study was designed to assess the efficiency of radiology reporting in the Royal Adelaide Hospital Department of Radiology, which introduced online reporting in November 1994. Seventeen radiologists were monitored without their knowledge, and recordings were made of the times between report dictation and report typing, and the time that the report waited on computer for verification. The total median values for verification time for 9/17 radiologists were less than 12 h and for 14/17 were less than 24h. On average, reports were available from all reporting areas within 24 h. However, some reports waited up to 13 and 14 days to be verified and to be available on computer for treating clinicians. This report demonstrates that on average rapid reporting is occurring, however some areas need to be considered further to maximize efficiency.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.